XML 51 R27.htm IDEA: XBRL DOCUMENT v3.22.4
Segments of Business and Geographic Areas
 12 Months Ended
Jan. 02, 2022
Segment Reporting [Abstract]  
Segments of Business and Geographic Areas Segments of Business* and Geographic Areas
 Sales to Customers % Change
(Dollars in Millions)202220212020’22 vs. ’21’21 vs. ’20
CONSUMER HEALTH (1)
   
OTC
     U.S.$2,782 2,594 2,460 7.3 %5.4 
     International3,249 3,034 2,761 7.1 9.9 
     Worldwide 6,031 5,627 5,221 7.2 7.8 
Skin Health/Beauty
     U.S.2,337 2,400 2,350 (2.6)2.1 
     International2,015 2,141 2,100 (5.9)1.9 
     Worldwide 4,352 4,541 4,450 (4.2)2.0 
Oral Care
     U.S.635 637 683 (0.3)(6.7)
     International871 1,008 958 (13.6)5.1 
     Worldwide 1,505 1,645 1,641 (8.5)0.2 
Baby Care
     U.S.357 378 376 (5.5)0.5 
     International1,104 1,188 1,141 (7.1)4.1 
     Worldwide 1,461 1,566 1,517 (6.7)3.2 
Women's Health
     U.S.13 13 13 1.7 (1.6)
     International891 905 888 (1.5)1.8 
     Worldwide 904 917 901 (1.5)1.8 
Wound Care/Other
     U.S.475 495 480 (4.0)3.1 
     International224 243 240 (8.0)1.7 
     Worldwide 700 739 720 (5.3)2.6 
TOTAL CONSUMER HEALTH
     U.S.6,599 6,516 6,362 1.3 2.4 
     International8,354 8,519 8,088 (1.9)5.3 
     Worldwide 14,953 15,035 14,450 (0.5)4.0 


PHARMACEUTICAL(1)
Immunology
     U.S.11,036 10,843 10,175 1.8 6.6 
     International5,899 5,907 4,880 (0.1)21.0 
     Worldwide 16,935 16,750 15,055 1.1 11.3 
     REMICADE
     U.S.1,417 2,019 2,508 (29.8)(19.5)
     U.S. Exports204 236 346 (13.6)(31.9)
     International722 935 893 (22.8)4.8 
     Worldwide 2,343 3,190 3,747 (26.6)(14.9)
     SIMPONI / SIMPONI ARIA
     U.S.1,166 1,127 1,155 3.5 (2.4)
     International1,017 1,148 1,088 (11.4)5.5 
     Worldwide 2,184 2,276 2,243 (4.0)1.4 
     STELARA
     U.S.6,388 5,938 5,240 7.6 13.3 
     International3,335 3,196 2,467 4.4 29.6 
     Worldwide 9,723 9,134 7,707 6.5 18.5 
     TREMFYA
     U.S.1,844 1,503 926 22.7 62.3 
     International824 624 421 32.0 48.2 
     Worldwide 2,668 2,127 1,347 25.4 57.9 
     OTHER IMMUNOLOGY
     U.S.17 21 — (18.4)**
     International0 3 11 **(73.3)
     Worldwide 17 24 11 (28.2)**
Infectious Diseases
     U.S.1,680 2,249 1,735 (25.3)29.7 
     International3,769 3,576 1,808 5.4 97.8 
     Worldwide 5,449 5,825 3,543 (6.5)64.4 
     COVID-19 VACCINE
U.S.120 634 — (81.1)**
International2,059 1,751 — 17.6 **
Worldwide2,179 2,385 — (8.6)**
     EDURANT / rilpivirine
     U.S.36 41 44 (10.8)(7.6)
     International972 953 920 2.0 3.6 
     Worldwide 1,008 994 964 1.5 3.1 
     PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
     U.S.1,494 1,508 1,587 (1.0)(4.9)
     International449 575 597 (21.9)(3.6)
     Worldwide 1,943 2,083 2,184 (6.7)(4.6)
     OTHER INFECTIOUS DISEASES
     U.S.30 66 104 (55.5)(36.0)
     International289 297 292 (2.6)1.7 
     Worldwide 318 363 396 (12.3)(8.3)
Neuroscience
     U.S.3,570 3,347 3,091 6.7 8.3 
     International3,323 3,641 3,435 (8.7)6.0 
     Worldwide 6,893 6,988 6,526 (1.4)7.1 
     CONCERTA / methylphenidate
     U.S.151 172 183 (12.5)(5.8)
     International493 495 439 (0.4)12.8 
     Worldwide 644 667 622 (3.5)7.3 
       INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA
     U.S.2,714 2,550 2,314 6.5 10.2 
     International1,426 1,472 1,339 (3.1)10.0 
     Worldwide 4,140 4,022 3,653 3.0 10.1 
     RISPERDAL CONSTA
     U.S.257 287 296 (10.4)(2.9)
     International228 305 346 (25.3)(11.8)
     Worldwide 485 592 642 (18.1)(7.7)
     OTHER NEUROSCIENCE
     U.S.447 338 298 32.4 13.3 
     International1,176 1,368 1,312 (14.1)4.3 
     Worldwide 1,623 1,706 1,610 (4.9)6.0 
Oncology
     U.S.6,930 5,958 5,092 16.3 17.0 
     International9,052 8,590 7,275 5.4 18.1 
     Worldwide 15,983 14,548 12,367 9.9 17.6 
     DARZALEX
     U.S.4,210 3,169 2,232 32.8 42.0 
     International3,767 2,854 1,958 32.0 45.8 
     Worldwide 7,977 6,023 4,190 32.4 43.8 
     ERLEADA
     U.S.968 813 583 19.2 39.3
     International913 478 176 *** *
     Worldwide1,881 1,291 760 45.7 70.0 
     IMBRUVICA
     U.S.1,390 1,747 1,821 (20.4)(4.0)
     International2,394 2,622 2,307 (8.7)13.6 
     Worldwide 3,784 4,369 4,128 (13.4)5.8 
     ZYTIGA /abiraterone acetate
     U.S.74 119 373 (37.8)(68.1)
     International1,696 2,178 2,097 (22.1)3.9 
     Worldwide 1,770 2,297 2,470 (22.9)(7.0)
     OTHER ONCOLOGY
     U.S.289 110 83 **31.7 
     International283 458 738 (38.3)(37.9)
     Worldwide 571 568 821 0.6 (30.8)
Pulmonary Hypertension
     U.S.2,346 2,365 2,133 (0.8)10.9 
     International1,071 1,085 1,015 (1.3)6.9 
     Worldwide 3,417 3,450 3,148 (1.0)9.6 
     OPSUMIT
     U.S.1,132 1,147 1,008 (1.3)13.7 
     International651 672 631 (3.2)6.6 
     Worldwide 1,783 1,819 1,639 (2.0)11.0 
     UPTRAVI
     U.S.1,104 1,056 955 4.5 10.5 
     International218 181 138 20.4 31.1 
     Worldwide 1,322 1,237 1,093 6.9 13.1 
     OTHER
     U.S.110 163 169 (32.3)(3.7)
     International202 232 247 (12.8)(5.9)
     Worldwide 313 395 416 (20.8)(5.0)
Cardiovascular / Metabolism / Other
     U.S.3,042 3,192 3,509 (4.7)(9.0)
     International845 927 1,025 (8.9)(9.6)
     Worldwide 3,887 4,119 4,534 (5.6)(9.2)
     XARELTO
     U.S.2,473 2,438 2,345 1.4 4.0 
     International— — — — — 
     Worldwide 2,473 2,438 2,345 1.4 4.0 
     INVOKANA/ INVOKAMET
     U.S.193 308 564 (37.4)(45.4)
     International255 254 231 0.1 9.9 
     Worldwide 448 563 795 (20.4)(29.3)
     OTHER(2)
     U.S.376 446 600 (15.5)(25.7)
     International590 673 794 (12.3)(15.2)
     Worldwide 966 1,119 1,394 (13.6)(19.7)
TOTAL PHARMACEUTICAL
     U.S.28,604 27,954 25,735 2.3 8.6 
     International23,959 23,726 19,440 1.0 22.0 
     Worldwide 52,563 51,680 45,175 1.7 14.4 
MEDTECH*(3)
Interventional Solutions
     U.S.2,169 1,836 1,452 18.2 26.4 
     International2,131 2,135 1,594 (0.2)34.0 
     Worldwide 4,300 3,971 3,046 8.3 30.4 
Orthopaedics
     U.S.5,321 5,126 4,779 3.8 7.3 
     International3,267 3,462 2,984 (5.6)16.0 
     Worldwide 8,587 8,588 7,763 0.0 10.6 
     HIPS
     U.S.943 878 793 7.3 10.7 
     International571 602 487 (5.1)23.6 
     Worldwide 1,514 1,480 1,280 2.3 15.6 
     KNEES
     U.S.851 787 743 8.2 5.9 
     International508 538 427 (5.7)26.1 
     Worldwide 1,359 1,325 1,170 2.6 13.3 
     TRAUMA
     U.S.1,882 1,819 1,648 3.5 10.4 
     International989 1,066 966 (7.2)10.4 
     Worldwide 2,871 2,885 2,614 (0.5)10.4 
     SPINE, SPORTS & OTHER
     U.S.1,645 1,642 1,595 0.2 2.9 
     International1,198 1,256 1,104 (4.6)13.8 
     Worldwide 2,843 2,898 2,699 (1.9)7.4 
Surgery
     U.S.3,897 3,867 3,249 0.8 19.0 
     International5,793 5,945 4,983 (2.6)19.3 
     Worldwide 9,690 9,812 8,232 (1.2)19.2 
     ADVANCED
     U.S.1,784 1,761 1,535 1.3 14.9 
     International2,785 2,861 2,304 (2.6)24.1 
     Worldwide 4,569 4,622 3,839 (1.1)20.4 
     GENERAL
     U.S.2,113 2,105 1,714 0.4 22.7 
     International3,008 3,085 2,679 (2.5)15.2 
     Worldwide 5,121 5,190 4,392 (1.3)18.1 
Vision
     U.S.1,990 1,857 1,557 7.2 19.3 
     International2,859 2,831 2,362 1.0 19.8 
     Worldwide 4,849 4,688 3,919 3.4 19.6 
     CONTACT LENSES / OTHER
     U.S.1,522 1,398 1,213 8.9 15.2 
     International2,022 2,043 1,781 (1.0)14.7 
     Worldwide 3,543 3,440 2,994 3.0 14.9 
     SURGICAL
     U.S.468 459 344 2.0 33.5 
     International837 788 581 6.2 35.7 
     Worldwide 1,306 1,248 925 4.6 34.9 
TOTAL MEDTECH   
     U.S.13,377 12,686 11,036 5.4 14.9 
     International14,050 14,374 11,923 (2.3)20.6 
     Worldwide 27,427 27,060 22,959 1.4 17.9 
WORLDWIDE   
     U.S.48,580 47,156 43,133 3.0 9.3 
     International46,363 46,619 39,451 (0.6)18.2 
     Worldwide $94,943 93,775 82,584 1.3 %13.6 
*Certain prior year amounts have been reclassified to conform to current year presentation
**Percentage greater than 100% or not meaningful
(1)Approximately $0.4 billion in both the fiscal 2021 and 2020, of certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes
(2) Inclusive of PROCRIT / EPREX which was previously disclosed separately
(3) Previously referred to as Medical Devices

 Income (Loss) Before Tax*Identifiable Assets
(Dollars in Millions)
2022 (3)
2021 (4)
2020 (5)
20222021
Consumer Health$2,930 1,573 (852)$24,068 25,081 
Pharmaceutical15,901 17,969 15,250 58,436 64,376 
MedTech4,607 4,373 3,044 70,956 53,372 
Total23,438 23,915 17,442 153,460 142,829 
Less: Expense not allocated to segments (1)
624 1,072 945 
Less: Consumer Health separation costs1,089 67 
General corporate (2)
33,918 39,189 
Worldwide total$21,725 22,776 16,497 $187,378 182,018 
*Income before tax of approximately $0.2 billion and $0.2 billion in the fiscal years 2021 and 2020, respectively, has been reclassified as certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes

Additions to Property,
Plant & Equipment		Depreciation and
Amortization
(Dollars in Millions)202220212020202220212020
Consumer Health$323 331 248 $658 759 785 
Pharmaceutical1,374 1,198 863 3,687 4,029 4,006 
MedTech2,120 1,933 1,980 2,302 2,286 2,140 
Segments total3,817 3,462 3,091 6,647 7,074 6,931 
General corporate192 190 256 323 316 300 
Worldwide total$4,009 3,652 3,347 $6,970 7,390 7,231 
 Sales to Customers
Long-Lived Assets (6)
(Dollars in Millions)20222021202020222021
United States$48,580 47,156 43,133 $66,283 48,586 
Europe23,449 23,594 18,980 38,774 43,257 
Western Hemisphere excluding U.S. 6,125 5,750 5,335 2,737 2,708 
Asia-Pacific, Africa16,789 17,275 15,136 4,431 5,035 
Segments total94,943 93,775 82,584 112,225 99,586 
General corporate1,134 1,014 
Other non long-lived assets74,019 81,418 
Worldwide total$94,943 93,775 82,584 $187,378 182,018 
See Note 1 for a description of the segments in which the Company operates.
Export sales are not significant. In fiscal year 2022, the Company utilized three wholesalers distributing products for all three segments that represented approximately 16.5%, 13.0% and 12.0% of the total consolidated revenues. In fiscal year 2021, the Company had three wholesalers distributing products for all three segments that represented approximately 14.0%, 11.0% and 11.0% of the total consolidated revenues. In fiscal year 2020, the Company had three wholesalers distributing products for all three segments that represented approximately 16.0%, 12.0%, and 12.0% of the total consolidated revenues.
(1)Amounts not allocated to segments include interest (income) expense and general corporate (income) expense.
(2)General corporate includes cash, cash equivalents and marketable securities.
(3)Consumer Health includes:
•Litigation expense of $0.2 billion
•A restructuring related charge of $0.1 billion
Pharmaceutical includes:
•One-time COVID-19 Vaccine manufacturing exit related costs of $1.5 billion
•An intangible asset impairment charge of approximately $0.8 billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS) acquired with the acquisition of XBiotech, Inc. in the fiscal year 2020. Additional information regarding efficacy of the AD and HS indications became available which led the Company to the decision to terminate the development of bermekimab for AD and HS
•Litigation expense of $0.1 billion
•Loss of $0.7 billion related to the change in the fair value of securities
•A restructuring related charge of $0.1 billion
MedTech includes:
•Litigation expense of $0.6 billion primarily for pelvic mesh related costs
•A restructuring related charge of $0.3 billion
•Acquisition and integration related costs of $0.3 billion primarily related to the acquisition of Abiomed
•A Medical Device Regulation charge of $0.3 billion
(4)    Consumer Health includes:
•Litigation expense of $1.6 billion, primarily talc related costs
•A restructuring related charge of $0.1 billion
Pharmaceutical includes:
•Litigation expense of $0.6 billion, primarily related to Risperdal Gynecomastia
•Divestiture gains of $0.6 billion
•Gains of $0.5 billion related to the change in the fair value of securities
•A restructuring related charge of $0.1 billion
MedTech includes:
•A restructuring related charge of $0.3 billion
•An in-process research and development expense of $0.9 billion related to Ottava
•A Medical Device Regulation charge of $0.2 billion
•Litigation expense of $0.1 billion
(5)    Consumer Health includes:
•Litigation expense of $3.9 billion, primarily talc related costs and certain settlements.
Pharmaceutical includes:
•Litigation expense of $0.8 billion, primarily related to the agreement in principle to settle opioid litigation
•A gain of $0.5 billion related to the change in the fair value of securities
•A restructuring related charge of $0.1 billion
MedTech includes:
•A contingent consideration reversal of $1.1 billion related to the timing of certain developmental milestones associated with the Auris Health acquisition.
•Litigation expense of $0.3 billion
•A restructuring related charge of $0.3 billion
•An in-process research and development expense of $0.2 billion
•A Medical Device Regulation charge of $0.1 billion
(6) Long-lived assets include property, plant and equipment, net for fiscal years 2022, and 2021 of $19,803 and $18,962, respectively, and intangible assets and goodwill, net for fiscal years 2022 and 2021 of $93,556 and $81,638, respectively.